FIELD: medicine. SUBSTANCE: the present innovation deals with methods to obtain analogs of insulin, their application, in particular, in pharmaceutical preparative forms for treating insulindependent diabetes mellitus (IDDM) and, also, non-insulin- dependent diabetes mellitus (NIDDM). Analogs of insulin are of increased capacity for zinc-binding and, also, to their resistant complexes with zinc that are of delayed profile of action against human insulin. EFFECT: higher efficiency. 60 cl, 9 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
| PORCINE TRYPSIN OPTIONS | 2019 |
|
RU2783315C2 |
| ANTIBODIES AGAINST ANGPTL3/8 COMPLEX AND THEIR APPLICATION METHODS | 2019 |
|
RU2791034C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
